September 5, 2024Advanced Healthcare MaterialsOpen Access

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

JLJinzhao LiuChina University of Geosciences QLQingyang Lyu MWMeicen WuUniversity of Hong Kong

Discussion

Member takes

Implication

Preclinical study demonstrates carrier-free mTOR-inhibiting nanodrugs reverse hypoxia-induced angiogenesis in breast cancer models, highlighting improved photodynamic immunotherapy.

Key Points

Carrier-free nanodrugs combine Torin 1 and Verteporfin to reverse hypoxia-driven angiogenesis while triggering potent immunogenic cell death in breast cancer.
In vitro and in vivo assessments demonstrate that self-assembled nanoparticles generate reactive oxygen species and elicit strong antitumor immune responses.
Dual inhibition of the mTOR signaling pathway and photodynamic therapy enables microenvironment remodeling, though murine models require clinical validation.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e5943fb6db64358752eeb5 https://doi.org/10.1002/adhm.202402357

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates carrier-free mTOR-inhibiting nanodrugs reverse hypoxia-induced angiogenesis in breast cancer models, highlighting improved photodynamic immunotherapy.

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider